GlassScriptPhysician profile
Miguel A Petrozzi
NPI 1366587727
$3,149.55
in general payments reported to CMS, 2019-2025
24 companies · $399 in 2025
The $399 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $87.40 · 2021: $309 · 2022: $679 · 2023: $648 · 2024: $698 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,745.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $648.99 | 2019-2024 | Spinraza, Spinraza |
| Ucb, INC. | $633.18 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Neurelis, INC. | $581.25 | 2020-2025 | Valtoco |
| Immedica Pharma US, INC. | $166.01 | 2022-2024 | |
| Livanova USA, INC. | $148.60 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Eisai INC. | $135.87 | 2021-2022 | |
| Biomarin Pharmaceutical INC. | $129.99 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $124.87 | 2023-2025 | |
| Greenwich Biosciences, INC. | $91.52 | 2020-2021 | |
| Otter Pharmaceuticals, LLC | $78.60 | 2024-2025 | Sympazan |
| Itf Therapeutics LLC | $65.99 | 2024-2025 | |
| Genentech USA, INC. | $53.97 | 2022-2023 | Evrysdi |
| Sarepta Therapeutics, INC. | $52.98 | 2023-2024 | Exondys 51, Elevidys |
| Shire North American Group INC | $44.61 | 2019 | |
| Corium, LLC | $27.41 | 2023 | Azstarys |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocodex, INC. | $24.64 | 2023 | Diacomit |
| Supernus Pharmaceuticals, INC. | $24.04 | 2019 | |
| Pyros Pharmaceuticals, INC. | $21.28 | 2024 | Vigpoder |
| Zogenix INC. | $17.30 | 2021 | |
| Xeris Pharmaceuticals, INC. | $16.90 | 2021 | |
| Sk Life Science, INC. | $16.84 | 2023 | |
| Springworks Therapeutics, INC. | $16.55 | 2025 | |
| Sumitomo Pharma America, INC. | $15.38 | 2024 | Aptiom |
| Strongbridge US INC. | $12.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miguel Petrozzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.